MX2009009540A - Inhibidores de metaloproteasa que contienen una porcion heterociclica. - Google Patents
Inhibidores de metaloproteasa que contienen una porcion heterociclica.Info
- Publication number
- MX2009009540A MX2009009540A MX2009009540A MX2009009540A MX2009009540A MX 2009009540 A MX2009009540 A MX 2009009540A MX 2009009540 A MX2009009540 A MX 2009009540A MX 2009009540 A MX2009009540 A MX 2009009540A MX 2009009540 A MX2009009540 A MX 2009009540A
- Authority
- MX
- Mexico
- Prior art keywords
- mmp
- heterocyclic moiety
- metalloprotease inhibitors
- inhibitors containing
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención se refiere generalmente a compuestos que inhiben la metaloproteasa heterocíclicos de la fórmula (I). (ver fórmula (I)) Más particularmente, la presente invención proporciona una clase nueva de compuestos que inhiben MMP 3, MMP 8 y/o MMP 13 heterocíclicos con una porción de benzoxazinona o esquearamida, que exhiben una potencia y selectividad incrementada en relación a los inhibidores MMP 13, MMP 8 y MMP 3 actualmente conocidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90556507P | 2007-03-07 | 2007-03-07 | |
PCT/US2008/003196 WO2008109181A2 (en) | 2007-03-07 | 2008-03-07 | Metalloprotease inhibitors containing a heterocyclic moiety |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009009540A true MX2009009540A (es) | 2009-09-16 |
Family
ID=39551667
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009009541A MX2009009541A (es) | 2007-03-07 | 2008-03-07 | Inhibidores de metaloproteasa que contienen una porcion heterociclica. |
MX2009009552A MX2009009552A (es) | 2007-03-07 | 2008-03-07 | Inhibidores de metaloproteasa que contienen una porcion heterociclica. |
MX2009009540A MX2009009540A (es) | 2007-03-07 | 2008-03-07 | Inhibidores de metaloproteasa que contienen una porcion heterociclica. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009009541A MX2009009541A (es) | 2007-03-07 | 2008-03-07 | Inhibidores de metaloproteasa que contienen una porcion heterociclica. |
MX2009009552A MX2009009552A (es) | 2007-03-07 | 2008-03-07 | Inhibidores de metaloproteasa que contienen una porcion heterociclica. |
Country Status (7)
Country | Link |
---|---|
US (5) | US20080221093A1 (es) |
EP (3) | EP2125816A2 (es) |
JP (3) | JP2010520293A (es) |
AU (3) | AU2008223348A1 (es) |
CA (3) | CA2680173A1 (es) |
MX (3) | MX2009009541A (es) |
WO (5) | WO2008109178A1 (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7728031B2 (en) * | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
WO2008063668A1 (en) * | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
JP5665540B2 (ja) * | 2007-09-11 | 2015-02-04 | アッヴィ・インコーポレイテッド | オクタヒドロ−ピロロ[3,4−b]ピロールn−オキシド |
JP5432982B2 (ja) | 2008-03-31 | 2014-03-05 | 武田薬品工業株式会社 | アポトーシスシグナル調節キナーゼ1阻害剤 |
US8242106B2 (en) | 2008-08-01 | 2012-08-14 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
ES2705101T3 (es) | 2008-11-06 | 2019-03-21 | Ventirx Pharmaceuticals Inc | Métodos de síntesis de derivados de benzazepinas |
WO2010111626A2 (en) * | 2009-03-27 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
MX2011012345A (es) * | 2009-05-22 | 2012-01-31 | Exelixis Inc | Inhibidores de pi3k/mtor basados en benzoxazepinas contra enfermedades proliferativas. |
RU2016108987A (ru) | 2009-08-18 | 2018-11-26 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора |
PT2467377T (pt) | 2009-08-18 | 2017-04-04 | Array Biopharma Inc | Benzoazepinas substituídas como moduladores de recetores de tipo toll |
NZ599290A (en) * | 2009-10-16 | 2014-10-31 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
CN102712657A (zh) | 2009-10-16 | 2012-10-03 | Rib-X制药公司 | 抗微生物化合物和其制备和使用方法 |
BR112012010752B1 (pt) | 2009-11-05 | 2021-07-20 | University Of Notre Dame Du Lac | Compostos imidazo[1,2-a]piridina |
EP2377850A1 (en) * | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
MX2012012353A (es) * | 2010-04-23 | 2013-02-07 | Kineta Inc | Compuestos anti-virales. |
US8440662B2 (en) | 2010-10-31 | 2013-05-14 | Endo Pharmaceuticals, Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
BR112014004963A2 (pt) | 2011-09-02 | 2017-03-21 | Novartis Ag | sal de colina do composto anti-inflamatório ciclobutanodiona substituído |
EP2794600B1 (en) | 2011-12-22 | 2017-12-06 | Novartis AG | 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis |
BR112014030812B1 (pt) | 2012-06-13 | 2022-11-08 | Incyte Holdings Corporation | Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
EP3033336B1 (en) | 2013-08-14 | 2018-05-30 | Kalvista Pharmaceuticals Limited | Inhibitors of plasma kallikrein |
AU2014315045A1 (en) | 2013-09-09 | 2016-03-24 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
CA2923214A1 (en) | 2013-09-09 | 2015-03-12 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
WO2015092420A1 (en) | 2013-12-20 | 2015-06-25 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
NO2699580T3 (es) | 2014-01-24 | 2018-02-24 | ||
US10752640B2 (en) * | 2014-08-01 | 2020-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CN114807307A (zh) | 2014-10-29 | 2022-07-29 | 10X 基因组学有限公司 | 用于靶核酸测序的方法和组合物 |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
SG11201707346RA (en) | 2015-03-11 | 2017-10-30 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
AU2016324598A1 (en) | 2015-09-17 | 2018-03-15 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Cxcr2抑制劑 |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
RU2020140891A (ru) | 2016-05-31 | 2021-02-10 | Калвиста Фармасьютикалз Лимитед | Производные пиразола в качестве ингибиторов калликреина |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
US10604541B2 (en) | 2016-07-22 | 2020-03-31 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
KR20190097074A (ko) * | 2016-12-27 | 2019-08-20 | 다이이찌 산쿄 가부시키가이샤 | 피리미딘 유도체 |
SG11201906803WA (en) * | 2017-01-27 | 2019-08-27 | Genfit | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2h-1,4-benzoxa zin-7-yl)acetamide derivatives and related compounds as ror-gamma modulators for treating autoimmune diseases |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CN111194317A (zh) | 2017-07-28 | 2020-05-22 | 林伯士拉克许米公司 | Tyk2抑制剂与其用途 |
EP3717477B1 (en) * | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
SI3716952T1 (sl) | 2017-11-29 | 2022-04-29 | Kalvista Pharmaceuticals Limited | Farmacevtske oblike, ki obsegajo zaviralec plazemskega kalikreina |
AU2019205786B2 (en) | 2018-01-08 | 2023-12-14 | Chemocentryx, Inc. | Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2 |
SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
KR20210018265A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 고체 형태 및 이의 제조 방법 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
EP4069695A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Derivatives of an fgfr inhibitor |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
AU2022256476A1 (en) | 2021-04-16 | 2023-10-12 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
CN113651767B (zh) * | 2021-09-18 | 2023-06-09 | 江西中医药大学 | 一种苯并异噁唑类杂环化合物及其制备方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6559152B2 (en) * | 1998-10-13 | 2003-05-06 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
KR20070008709A (ko) * | 2004-04-30 | 2007-01-17 | 다케다 야쿠힌 고교 가부시키가이샤 | 이종환식 아미드 화합물 및 이의 mmp-13 저해제로서의용도 |
PE20060653A1 (es) * | 2004-08-31 | 2006-09-27 | Glaxo Group Ltd | Derivados triciclicos condensados como moduladores del receptor 5-ht1 |
US20060173183A1 (en) * | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
JP2008531690A (ja) | 2005-02-28 | 2008-08-14 | レノビス, インコーポレイテッド | イオンチャネルリガンドとしてのアミド誘導体並びにそれを使用する医薬組成物及び方法 |
US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
WO2006128184A2 (en) * | 2005-05-20 | 2006-11-30 | Alantos-Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
JP5169220B2 (ja) | 2005-11-30 | 2013-03-27 | アステラス製薬株式会社 | 2−アミノベンズアミド誘導体 |
US20070155739A1 (en) * | 2005-12-30 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Substituted bis-amide metalloprotease inhibitors |
WO2008002671A2 (en) * | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
US20080176870A1 (en) * | 2006-11-20 | 2008-07-24 | Bert Nolte | Heterobicyclic metalloprotease inhibitors |
WO2008063668A1 (en) * | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
AU2007321923A1 (en) * | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic matrix metalloprotease inhibitors |
-
2008
- 2008-03-07 EP EP08726687A patent/EP2125816A2/en not_active Withdrawn
- 2008-03-07 JP JP2009552768A patent/JP2010520293A/ja not_active Withdrawn
- 2008-03-07 WO PCT/US2008/003192 patent/WO2008109178A1/en active Application Filing
- 2008-03-07 MX MX2009009541A patent/MX2009009541A/es not_active Application Discontinuation
- 2008-03-07 EP EP08726691A patent/EP2139887A2/en not_active Withdrawn
- 2008-03-07 JP JP2009552767A patent/JP2010520292A/ja not_active Withdrawn
- 2008-03-07 WO PCT/US2008/003194 patent/WO2008109179A1/en active Application Filing
- 2008-03-07 US US12/074,917 patent/US20080221093A1/en not_active Abandoned
- 2008-03-07 CA CA002680173A patent/CA2680173A1/en not_active Abandoned
- 2008-03-07 AU AU2008223348A patent/AU2008223348A1/en not_active Abandoned
- 2008-03-07 MX MX2009009552A patent/MX2009009552A/es not_active Application Discontinuation
- 2008-03-07 US US12/074,925 patent/US20080221128A1/en not_active Abandoned
- 2008-03-07 CA CA002680312A patent/CA2680312A1/en not_active Abandoned
- 2008-03-07 US US12/074,918 patent/US20080221094A1/en not_active Abandoned
- 2008-03-07 MX MX2009009540A patent/MX2009009540A/es not_active Application Discontinuation
- 2008-03-07 CA CA002680177A patent/CA2680177A1/en not_active Abandoned
- 2008-03-07 AU AU2008223351A patent/AU2008223351A1/en not_active Abandoned
- 2008-03-07 EP EP08726692A patent/EP2134693A2/en not_active Withdrawn
- 2008-03-07 WO PCT/US2008/003196 patent/WO2008109181A2/en active Application Filing
- 2008-03-07 US US12/075,070 patent/US20080221095A1/en not_active Abandoned
- 2008-03-07 US US12/074,994 patent/US7691851B2/en not_active Expired - Fee Related
- 2008-03-07 WO PCT/US2008/003191 patent/WO2008109177A2/en active Application Filing
- 2008-03-07 WO PCT/US2008/003195 patent/WO2008109180A2/en active Application Filing
- 2008-03-07 JP JP2009552769A patent/JP2010520294A/ja not_active Withdrawn
- 2008-03-07 AU AU2008223352A patent/AU2008223352A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2009009552A (es) | 2009-09-28 |
JP2010520294A (ja) | 2010-06-10 |
AU2008223351A1 (en) | 2008-09-12 |
WO2008109177A3 (en) | 2009-01-22 |
WO2008109180A3 (en) | 2009-07-09 |
US7691851B2 (en) | 2010-04-06 |
EP2125816A2 (en) | 2009-12-02 |
US20080221128A1 (en) | 2008-09-11 |
WO2008109177A2 (en) | 2008-09-12 |
EP2139887A2 (en) | 2010-01-06 |
WO2008109181A2 (en) | 2008-09-12 |
WO2008109179A1 (en) | 2008-09-12 |
WO2008109181A3 (en) | 2008-12-11 |
AU2008223348A1 (en) | 2008-09-12 |
JP2010520292A (ja) | 2010-06-10 |
US20080221091A1 (en) | 2008-09-11 |
JP2010520293A (ja) | 2010-06-10 |
CA2680177A1 (en) | 2008-09-12 |
AU2008223352A1 (en) | 2008-09-12 |
WO2008109178A1 (en) | 2008-09-12 |
US20080221095A1 (en) | 2008-09-11 |
EP2134693A2 (en) | 2009-12-23 |
CA2680312A1 (en) | 2008-09-12 |
WO2008109180A2 (en) | 2008-09-12 |
CA2680173A1 (en) | 2008-09-12 |
US20080221093A1 (en) | 2008-09-11 |
US20080221094A1 (en) | 2008-09-11 |
MX2009009541A (es) | 2009-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009009540A (es) | Inhibidores de metaloproteasa que contienen una porcion heterociclica. | |
IL185275A0 (en) | N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same | |
MX2008014873A (es) | Inhibidores de metaloproteasa heterobiciclicas. | |
WO2008063671A3 (en) | Heterobicyclic metalloprotease inhibitors | |
TW200745028A (en) | Novel sulphonylpyrroles | |
MX2009003834A (es) | Derivados de pirrolidina como inhibidores de iap. | |
TW200720271A (en) | DNA-PK inhibitors | |
TW200745027A (en) | Novel sulphonylpyrroles | |
SG163585A1 (en) | Melanocortin receptor ligands | |
WO2008002671A3 (en) | Metalloprotease inhibitors | |
TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
MX2009005934A (es) | Compuestos organicos. | |
MX2007005408A (es) | Compuestos de aminoquinazolinas. | |
WO2007105058A3 (en) | Pyrazole compounds | |
MX2010006143A (es) | Azolilmetiloxiranos, su uso y agentes que lo contienen. | |
MX2009007077A (es) | Analogos de ciclopamina. | |
HK1096549A1 (en) | Imidazopyridine-derivatives as inducible no-synthase inhibitors | |
UA85505C2 (en) | Kinase inhibitors | |
TW200732281A (en) | Heterocyclic CETP inhibitors | |
WO2007019191A3 (en) | Thiazolopyrimidine kinase inhibitors | |
EA200970372A1 (ru) | Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение | |
UA107689C2 (en) | 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES | |
EA200801365A1 (ru) | Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины | |
EA200801366A1 (ru) | Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина | |
HK1096548A1 (en) | Imidazopyridine-derivatives as inductible no-synthase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |